Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy

Granuloma Annulare Clinical Trial

Official title:

Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00720980
• Other study ID #: IRB5074
• Status: Completed
• Start date: May 2008
• Est. completion date: July 2008

Study information

• Verified date: April 2024
• Source: Henry Ford Health System
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Granuloma annulare is a benign, usually self-limiting, cutaneous dermatosis, which typically presents as asymptomatic, flesh-colored or red papules, frequently arranged in an annular pattern on the distal extremities. Although localized granuloma annulare is most commonly observed, a generalized or disseminated form can occur. The etiology of granuloma annulare is unknown, however, multiple inciting factors have been proposed. The purpose of the investigators is to review the outcomes of treatment of granuloma annulare (GA) resistant to standard regimens that resolved after a 3-months treatment course of monthly rifampin, ofloxacin, and minocycline (ROM) therapy, successfully used to treat paucibacillary leprosy, a disease with clinical and histopathologic similarity to GA.

Description:

We will document the regimen treatment each patient has had and then review the following from the patient's chart to target our specific aims as outlined above. 1. What previous treatment options have been or/are currently being used? 2. How long did the patient take the treatment for? 3. Was the patient able to discontinue or become less dependent on prior treatment? 4. Was the disease process slowed by the treatment?; 5. Were there any side effects that the patient experienced with treatment?

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: July 2008
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with granuloma annulare who are resistent to the standard treatment.

Exclusion Criteria:

• Response to the standard treatment of granuloma annulare.

Related Conditions & MeSH terms

• Granuloma
• Granuloma Annulare

Locations

Country	Name	City	State
United States	Henry Ford Medical Center	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Henry Ford Health System

Country where clinical trial is conducted

United States, 

References & Publications (1)

Duarte AF, Mota A, Pereira MA, Baudrier T, Azevedo F. Generalized granuloma annulare--response to doxycycline. J Eur Acad Dermatol Venereol. 2009 Jan;23(1):84-5. doi: 10.1111/j.1468-3083.2008.02707.x. Epub 2008 Apr 1. No abstract available. — View Citation